- Home
- BOOT vs APGE Comparison
BOOT vs APGE Comparison
Compare BOOT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOOT | APGE |
|---|---|---|
| Founded | 1978 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.7B |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BOOT | APGE |
|---|---|---|
| Price | $147.09 | $82.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $223.09 | $109.67 |
| AVG Volume (30 Days) | 476.1K | ★ 517.2K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.50 | N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $776,854,000.00 | N/A |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $13.91 | N/A |
| P/E Ratio | $25.97 | ★ N/A |
| Revenue Growth | ★ 14.59 | N/A |
| 52 Week Low | $132.84 | $34.34 |
| 52 Week High | $210.25 | $95.32 |
Technical Indicators
Market Signals| Indicator | BOOT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 47.15 |
| Support Level | $133.18 | $80.52 |
| Resistance Level | $205.38 | $84.56 |
| Average True Range (ATR) | 6.67 | 3.53 |
| MACD | -1.88 | -0.73 |
| Stochastic Oscillator | 9.85 | 16.58 |
Price Performance
Historical ComparisonAbout BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.